Skip to main content
SpringerLink
Log in

The Efficacy and Tolerability of Commonly Used Agents to Prevent Recurrence of Atrial Fibrillation After Successful Cardioversion

  • Review Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

A number of therapeutic strategies exist for the restoration and maintenance of sinus rhythm in patients presenting with atrial fibrillation. The acute success rate with electrical cardioversion is high. However, many patients relapse into atrial fibrillation. A major challenge faced by those who care for patients with atrial fibrillation is the long-term maintenance of sinus rhythm whilst avoiding treatment-related adverse effects. This review examines the efficacy and tolerability of conventional anti-arrhythmic drugs for the secondary prevention of atrial fibrillation in the post-cardioversion period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gallagher MM, Camm AJ. Long-term management of atrial fibrillation. Clin Cardiol. 1997;20(4):381–90.

    CAS  PubMed  Google Scholar 

  2. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14(4):528–606.

    PubMed  Google Scholar 

  3. Gonna H, Gallagher MM, Guo XH, Yap YG, Hnatkova K, Malik M, Camm AJ. P wave abnormality predicts recurrence of atrial fibrillation after electrical cardioversion: a prospective study. Ann Noninvasive Electrocardiol. 2013;19:57–62.

    PubMed  Google Scholar 

  4. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347(23):1834–40.

    PubMed  Google Scholar 

  5. Gallagher MM, Guo XH, Poloniecki JD, Guan Yap Y, Ward D, Camm AJ. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. J Am Coll Cardiol. 2001;38(5):1498–504.

    CAS  PubMed  Google Scholar 

  6. Santini L, Gallagher MM, Papavasileiou LP, Romano V, Topa A, Di Battista L, et al. Transthoracic versus transesophageal cardioversion of atrial fibrillation under light sedation: a prospective randomized trial. Pacing Clin Electrophysiol. 2007;30(12):1469–75.

    PubMed  Google Scholar 

  7. Pisters R, Nieuwlaat R, Prins MH, Le Heuzey JY, Maggioni AP, Camm AJ, et al. Clinical correlates of immediate success and outcome at 1-year follow-up of real-world cardioversion of atrial fibrillation: the euro heart survey. Europace. 2012;14(5):666–74.

    PubMed  Google Scholar 

  8. Gallagher MM, Obel OA, Camm JA. Tachycardia-induced atrial myopathy: an important mechanism in the pathophysiology of atrial fibrillation? J Cardiovasc Electrophysiol. 1997;8(9):1065–74.

    CAS  PubMed  Google Scholar 

  9. Van Gelder IC, Hemels ME. The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm. Europace. 2006;8(11):943–9.

    PubMed  Google Scholar 

  10. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2012;5:CD005049.

    PubMed  Google Scholar 

  11. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol. 1991;68(1):41–6.

    PubMed  Google Scholar 

  12. Tieleman RG, Van Gelder IC, Crijns HJ, De Kam PJ, Van Den Berg MP, Haaksma J, et al. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodeling of the atria? J Am Coll Cardiol. 1998;31(1):167–73.

    CAS  PubMed  Google Scholar 

  13. Van Gelder IC, Tuinenburg AE, Schoonderwoerd BS, Tieleman RG, Crijns HJ. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol. 1999;84(9A):147R–51R.

    PubMed  Google Scholar 

  14. Agarwal SC, Pepper CB. Effect of amiodarone treatment on outcome after direct current cardioversion in atrial fibrillation: Should we cardiovert atrial fibrillation of longer duration. Int J Cardiol. 2007;117(3):406–7.

    CAS  PubMed  Google Scholar 

  15. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol. 1992;20(3):527–32.

    CAS  PubMed  Google Scholar 

  16. Saxonhouse SJ, Curtis AB. Risks and benefits of rate control versus maintenance of sinus rhythm. Am J Cardiol. 2003;91(6):27–32.

    Google Scholar 

  17. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825–33.

    CAS  PubMed  Google Scholar 

  18. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, et al. Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation. 2004;109(12):1509–13.

    PubMed  Google Scholar 

  19. Suman-Horduna I, Roy D, Frasure-Smith N, Talajic M, Lespérance F, Blondeau L, et al. Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure. J Am Coll Cardiol. 2013;61(4):455–60.

    PubMed  Google Scholar 

  20. Taylor CJ, Hodgkinson J, Hobbs FD. Rhythm control agents and adverse events in patients with atrial fibrillation. Int J Clin Pract. 2010;64(8):1069–75.

    CAS  PubMed  Google Scholar 

  21. Humphries KH, Kerr CR, Steinbuch M, Dorian P, Canadian Registry of Atrial Fibrillation investigators. Limitations to antiarrhythmic drug use in patients with atrial fibrillation. CMAJ. 2004;171(7):741–5.

    PubMed  PubMed Central  Google Scholar 

  22. Crijns HJ, Gosselink AT, Lie KI. Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: a randomized, double-blind study. PRODIS study group. Cardiovasc Drugs Ther. 1996;10(2):145–52.

    CAS  PubMed  Google Scholar 

  23. Karlson BW, Torstensson I, Abjörn C, Jansson SO, Peterson LE. Disopyramide in the maintenance of sinus rhythm after electroconversion of atrial fibrillation. A placebo-controlled one-year follow-up study. Eur Heart J. 1988;9(3):284–90.

    CAS  PubMed  Google Scholar 

  24. Nakazawa H, Lythall DA, Noh J, Ishikawa N, Sugino K, Ito K, Hardman SM. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J. 2000;21(4):327–33.

    CAS  PubMed  Google Scholar 

  25. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, et al. Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (FLEC-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet. 2012;380(9838):238–46.

    CAS  PubMed  Google Scholar 

  26. Gelder ICV, Crijns HJ, Gilst WHV, Wijk LMV, Hamer HP, Lie KI. Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol. 1989;64(19):1317–21.

    PubMed  Google Scholar 

  27. Taylor R, Gandhi MM, Lloyd G. Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. BMJ. 2010;340:b4684.

    PubMed  Google Scholar 

  28. Akiyama T, Pawitan Y, Greenberg H, Kuo CS, Reynolds-Haertle RA. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-q-wave acute myocardial infarction in the cardiac arrhythmia suppression trial. CAST investigators. Am J Cardiol. 1991;68(17):1551–5.

    CAS  PubMed  Google Scholar 

  29. Aliot E, Capucci A, Crijns HJ, Goette A, Tamargo J. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace. 2011;13(2):161–73.

    PubMed  PubMed Central  Google Scholar 

  30. Hellestrand KJ. Efficacy and safety of long-term oral flecainide acetate in patients with responsive supraventricular tachycardia. Am J Cardiol. 1996;77(3):83A–8A.

    CAS  PubMed  Google Scholar 

  31. Hopson JR, Buxton AE, Rinkenberger RL, Nademanee K, Heilman JM, Kienzle MG. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The flecainide supraventricular tachycardia study group. Am J Cardiol. 1996;77(3):72A–82A.

    CAS  PubMed  Google Scholar 

  32. Cros C, Skinner M, Moors J, Lainee P, Valentin JP. Detecting drug-induced prolongation of the QRS complex: new insights for cardiac safety assessment. Toxicol Appl Pharmacol. 2012;265(2):200–8.

    CAS  PubMed  Google Scholar 

  33. Antonelli D, Freedberg NA, Rosenfeld T. Acute loss of capture due to flecainide acetate. Pacing Clin Electrophysiol. 2001;24(7):1170.

    CAS  PubMed  Google Scholar 

  34. Almroth H, Andersson T, Fengsrud E, Friberg L, Linde P, Rosenqvist M, Englund A. The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. J Intern Med. 2011;270(3):281–90.

    CAS  PubMed  Google Scholar 

  35. Sullivan SD, Orme ME, Morais E, Mitchell SA. Interventions for the treatment of atrial fibrillation: a systematic literature review and meta-analysis. Int J Cardiol. 2013;165(2):229–36.

    PubMed  Google Scholar 

  36. Napoli C, Sorice P, Di Benedetto A, Di Ieso N, Liguori A. Propafenone in the conversion of atrial fibrillation in patients suffering from chronic renal failure. Am J Ther. 1997;4(4):130–3.

    CAS  PubMed  Google Scholar 

  37. Dogan A, Ergene O, Nazli C, Kinay O, Altinbas A, Ucarci Y, et al. Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: a randomized, placebo-controlled study. Acta Cardiol. 2004;59(3):255–61.

    PubMed  Google Scholar 

  38. Stroobandt R, Stiels B, Hoebrechts R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone atrial fibrillation trial investigators. Am J Cardiol. 1997;79(4):418–23.

    CAS  PubMed  Google Scholar 

  39. Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M, Santini M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol. 1996;28(3):700–6.

    CAS  PubMed  Google Scholar 

  40. Bellandi F, Simonetti I, Leoncini M, Frascarelli F, Giovannini T, Maioli M, Dabizzi RP. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol. 2001;88(6):640–5.

    CAS  PubMed  Google Scholar 

  41. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators. N Engl J Med. 2000;342(13):913–20.

    CAS  PubMed  Google Scholar 

  42. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1993;71(7):558–63.

    CAS  PubMed  Google Scholar 

  43. Podrid PJ, Anderson JL. Safety and tolerability of long-term propafenone therapy for supraventricular tachyarrhythmias. The propafenone multicenter study group. Am J Cardiol. 1996;78(4):430–4.

    CAS  PubMed  Google Scholar 

  44. Pritchett EL, Page RL, Carlson M, Undesser K, Fava G, Rythmol Atrial Fibrillation Trial (RAFT) Investigators. Efficacy and safety of sustained-release propafenone (propafenone SR) for patients with atrial fibrillation. Am J Cardiol. 2003;92(8):941–6.

    CAS  PubMed  Google Scholar 

  45. Meinertz T, Lip GY, Lombardi F, Sadowski ZP, Kalsch B, Camez A, et al. Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (the european rythmol/rytmonorm atrial fibrillation trial [ERAFT] study). Am J Cardiol. 2002;90(12):1300–6.

    CAS  PubMed  Google Scholar 

  46. el-Harari MB, Adams PC. Atrial flutter with 1:1 atrioventricular conduction caused by propafenone. Pacing Clin Electrophysiol. 1998;21(10):1999–2001.

    CAS  PubMed  Google Scholar 

  47. Kühlkamp V, Schirdewan A, Stangl K, Homberg M, Ploch M, Beck OA. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2000;36(1):139–46.

    PubMed  Google Scholar 

  48. Nergårdh AK, Rosenqvist M, Nordlander R, Frick M. Maintenance of sinus rhythm with metoprolol CR initiated before cardioversion and repeated cardioversion of atrial fibrillation: a randomized double-blind placebo-controlled study. Eur Heart J. 2007;28(11):1351–7.

    PubMed  Google Scholar 

  49. Katritsis DG, Panagiotakos DB, Karvouni E, Giazitzoglou E, Korovesis S, Paxinos G, et al. Comparison of effectiveness of carvedilol versus bisoprolol for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. Am J Cardiol. 2003;92(9):1116–9.

    CAS  PubMed  Google Scholar 

  50. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 1990;82(6):1932–9.

    CAS  PubMed  Google Scholar 

  51. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004;25(16):1385–94.

    PubMed  Google Scholar 

  52. Plewan A, Lehmann G, Ndrepepa G, Schreieck J, Alt EU, Schömig A, Schmitt C. Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation; sotalol vs bisoprolol. Eur Heart J. 2001;22(16):1504–10.

    CAS  PubMed  Google Scholar 

  53. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352(18):1861–72.

    CAS  PubMed  Google Scholar 

  54. Freemantle N, Lafuente-Lafuente C, Mitchell S, Eckert L, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace. 2011;13(3):329–45.

    PubMed  Google Scholar 

  55. Lombardi F, Borggrefe M, Ruzyllo W, Lüderitz B, A-COMET-II Investigators. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (azimilide-cardioversion maintenance trial-II) trial. Eur Heart J. 2006;27(18):2224–31.

    CAS  PubMed  Google Scholar 

  56. MacNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol. 1993;72(4):44A–50A.

    CAS  PubMed  Google Scholar 

  57. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD investigators. Survival with oral d-sotalol. Lancet. 1996;348(9019):7–12.

    CAS  PubMed  Google Scholar 

  58. Manios EG, Mavrakis HE, Kanoupakis EM, Kallergis EM, Dermitzaki DN, Kambouraki DC, Vardas PE. Effects of amiodarone and diltiazem on persistent atrial fibrillation conversion and recurrence rates: a randomized controlled study. Cardiovasc Drugs Ther. 2003;17(1):31–9.

    CAS  PubMed  Google Scholar 

  59. Channer KS, Birchall A, Steeds RP, Walters SJ, Yeo WW, West JN, et al. A randomized placebo-controlled trial of pre-treatment and short-or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J. 2004;25(2):144–50.

    CAS  PubMed  Google Scholar 

  60. Kanoupakis EM, Manios EG, Mavrakis HE, Tzerakis PG, Mouloudi HK, Vardas PE. Comparative effects of carvedilol and amiodarone on conversion and recurrence rates of persistent atrial fibrillation. Am J Cardiol. 2004;94(5):659–62.

    CAS  PubMed  Google Scholar 

  61. Galperin J, Elizari V, Chiale A, Molina T, Ledesma R, Scapin O, Blanco V. Efficacy of amiodarone for the termination of chronic atrial fibrillation and maintenance of normal sinus rhythm: a prospective, multicenter, randomized, controlled, double blind trial. J Cardiovasc Pharmacol Ther. 2001;6(4):341–50.

    CAS  PubMed  Google Scholar 

  62. Ahmed S, Rienstra M, Crijns HJ, Links TP, Wiesfeld AC, Hillege HL, et al. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA. 2008;300(15):1784–92.

    CAS  PubMed  Google Scholar 

  63. Ahmed S, Ranchor AV, Crijns HJ, Van Veldhuisen DJ, Van Gelder IC, CONVERT investigators. Effect of continuous versus episodic amiodarone treatment on quality of life in persistent atrial fibrillation. Europace. 2010;12(6):785–91.

    PubMed  Google Scholar 

  64. Lumer GB, Roy D, Talajic M, Couturier A, Lambert J, Frasure-Smith N, et al. Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. Eur Heart J. 2002;23(13):1050–6.

    CAS  PubMed  Google Scholar 

  65. Kochiadakis GE, Igoumenidis NE, Marketou ME, Kaleboubas MD, Simantirakis EN, Vardas PE. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart. 2000;84(3):251–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Kim MH, Smith PJ, Jhaveri M, Lin J, Klingman D. One-year treatment persistence and potential adverse events among patients with atrial fibrillation treated with amiodarone or sotalol: a retrospective claims database analysis. Clin Ther. 2011;33(11):1668–1681.e1.

    CAS  PubMed  Google Scholar 

  67. Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol. 2007;18(6):628–33.

    PubMed  PubMed Central  Google Scholar 

  68. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30(3):791–8.

    CAS  PubMed  Google Scholar 

  69. Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298(11):1312–22.

    CAS  PubMed  Google Scholar 

  70. Touboul P. Dronedarone for prevention of atrial fibrillation: a dose-ranging study. Eur Heart J. 2003;24(16):1481–7.

    CAS  PubMed  Google Scholar 

  71. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21(6):597–605.

    PubMed  Google Scholar 

  72. Said SM, Esperer HD, Kluba K, Genz C, Wiedemann AK, Boenigk H, et al. Efficacy and safety profile of dronedarone in clinical practice. Results of the magdeburg dronedarone registry (MADRE study). Int J Cardiol. 2013;167:2600–4.

    PubMed  Google Scholar 

  73. Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D, et al. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the efficacy and safety of dronedarone for the control of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008;156(3):527.e1-9.

    Google Scholar 

  74. Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus. J Am Coll Cardiol. 2009;54(12):1089–95.

    CAS  PubMed  Google Scholar 

  75. Löbe S, Salmáš J, John S, Kornej J, Husser D, Hindricks G, Bollmann A. Usefulness of dronedarone in patients with atrial arrhythmias. Am J Cardiol. 2013;111(9):1311–4.

    PubMed  Google Scholar 

  76. Jahn S, Zollner G, Lackner C, Stauber RE. Severe toxic hepatitis associated with dronedarone. Curr Drug Saf. 2013;8(3):201–2.

    CAS  PubMed  Google Scholar 

  77. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360(7):668–78.

    CAS  PubMed  Google Scholar 

  78. Køber L, Torp-Pedersen C, McMurray JJ, Gøtzsche O, Lévy S, Crijns H, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678–87.

    PubMed  Google Scholar 

  79. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365(24):2268–76.

    CAS  PubMed  Google Scholar 

  80. Lindholm CJA, Fredholm O, Möller SJ, Edvardsson N, Kronvall T, Pettersson T, et al. Sinus rhythm maintenance following DC cardioversion of atrial fibrillation is not improved by temporary precardioversion treatment with oral verapamil. Heart. 2004;90(5):534–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Hemels ME, Van Noord T, Crijns HJ, Van Veldhuisen DJ, Veeger NJ, Bosker HA, et al. Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation. J Am Coll Cardiol. 2006;48(5):1001–9.

    CAS  PubMed  Google Scholar 

  82. Villani G. Effects of diltiazem pretreatment on direct-current cardioversion in patients with persistent atrial fibrillation: a single-blind, randomized, controlled study. Am Heart J. 2000;140(3):437–43.

    Google Scholar 

  83. De Simone A, De Pasquale M, De Matteis C, Canciello M, Manzo M, Sabino L, et al. VErapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF study). Eur Heart J. 2003;24(15):1425–9.

    PubMed  Google Scholar 

  84. Simone AD, Stabile G, Vitale DF, Turco P, Stasio MD, Petrazzuoli F, et al. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol. 1999;34(3):810–4.

    PubMed  Google Scholar 

  85. Zardo F, Antonini-Canterin F, Brieda M, Hrovatin E, Pavan D, Burelli C, et al. Can short-term verapamil therapy reduce the recurrence of atrial fibrillation after successful low energy intracardiac cardioversion? Ital Heart J. 2001;2(7):513–8.

    CAS  PubMed  Google Scholar 

  86. Grecu M, Olteanu RO, Olteanu SS, Georgescu CA. Does treatment with ACE inhibitors prevent the long term recurrences of lone atrial fibrillation after cardioversion? Rom J Intern Med. 2007;45(1):29–33.

    CAS  PubMed  Google Scholar 

  87. Madrid AH, Bueno MG, Rebollo JM, Marín I, Peña G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106(3):331–6.

    CAS  PubMed  Google Scholar 

  88. Madrid AH, Marín IM, Cervantes CE, Morell EB, Estévez JE, Moreno G, et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst. 2004;5(3):114–20.

    CAS  PubMed  Google Scholar 

  89. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 2003;24(23):2090–8.

    CAS  PubMed  Google Scholar 

  90. Van Den Berg MP, Crijns HJ, Van Veldhuisen DJ, Griep N, De Kam PJ, Lie KI. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail. 1995;1(5):355–63.

    CAS  PubMed  Google Scholar 

  91. Tveit A, Grundvold I, Olufsen M, Seljeflot I, Abdelnoor M, Arnesen H, Smith P. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol. 2007;120(1):85–91.

    PubMed  Google Scholar 

  92. Belluzzi F, Sernesi L, Preti P, Salinaro F, Fonte ML, Perlini S. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol. 2009;53(1):24–9.

    CAS  PubMed  Google Scholar 

  93. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45(11):1832–9.

    CAS  PubMed  Google Scholar 

  94. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin–angiotensin system: a systematic review and meta-analysis. Am J Ther. 2008;15(1):36–43.

    PubMed  Google Scholar 

  95. Zhang Y, Zhang P, Mu Y, Gao M, Wang JR, Wang Y, et al. The role of renin–angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Clin Pharmacol Ther. 2010;88(4):521–31.

    CAS  PubMed  Google Scholar 

  96. Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin–angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55(21):2299–307.

    PubMed  Google Scholar 

  97. Li TJ, Zang WD, Chen YL, Geng N, Ma SM, Li XD. Renin–angiotensin system inhibitors for prevention of recurrent atrial fibrillation: A meta-analysis. Int J Clin Pract. 2013;67(6):536–43.

    CAS  PubMed  Google Scholar 

  98. Han M, Zhang Y, Sun S, Wang Z, Wang J, Xie X, et al. Renin–angiotensin system inhibitors prevent the recurrence of atrial fibrillation: a meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2013;62:405–15.

    CAS  PubMed  Google Scholar 

  99. Siu C-W, Lau C-P, Tse H-F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol. 2003;92(11):1343–5.

    CAS  PubMed  Google Scholar 

  100. Tveit A, Grundtvig M, Gundersen T, Vanberg P, Semb AG, Holt E, Gullestad L. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2004;93(6):780–2.

    CAS  PubMed  Google Scholar 

  101. Ozaydin M, Varol E, Aslan SM, Kucuktepe Z, Dogan A, Ozturk M, Altinbas A. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2006;97(10):1490–3.

    CAS  PubMed  Google Scholar 

  102. Humphries KH, Lee M, Sheldon R, Ramanathan K, Dorian P, Green M, et al. Statin use and recurrence of atrial fibrillation after successful cardioversion. Am Heart J. 2007;154(5):908–13.

    CAS  PubMed  Google Scholar 

  103. Naji F, Suran D, Kanic V, Vokac D, Sabovic M. Statins and amiodarone improve freedom from recurrence of atrial fibrillation after successful cardioversion. Med Sci Monit. 2009;15(9):CR494–8.

    CAS  PubMed  Google Scholar 

  104. Xia W, Yin Z, Li J, Song Y, Qu X. Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol. 2009;32(12):1562–6.

    PubMed  Google Scholar 

  105. García-Fernández A, Marín F, Mainar L, Roldán V, Martínez JG. Effect of statins on preventing recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2006;98(9):1299–300.

    PubMed  Google Scholar 

  106. Almroth H, Höglund N, Boman K, Englund A, Jensen S, Kjellman B, et al. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur Heart J. 2009;30(7):827–33.

    CAS  PubMed  Google Scholar 

  107. Demir K, Can I, Koc F, Vatankulu MA, Ayhan S, Akilli H, et al. Atorvastatin given prior to electrical cardioversion does not affect the recurrence of atrial fibrillation in patients with persistent atrial fibrillation who are on antiarrhythmic therapy. Med Princ Pract. 2011;20(5):464–9.

    PubMed  Google Scholar 

  108. Negi S, Shukrullah I, Veledar E, Bloom HL, Jones DP, Dudley SC. Statin therapy for the prevention of atrial fibrillation trial (stop AF trial). J Cardiovasc Electrophysiol. 2011;22(4):414–9.

    PubMed  PubMed Central  Google Scholar 

  109. Naji F, Suran D, Kanic V, Vokac D, Sabovic M. Comparison of atorvastatin and simvastatin in prevention of atrial fibrillation after successful cardioversion. Int Heart J. 2009;50(2):153–60.

    CAS  PubMed  Google Scholar 

  110. Fauchier L, Pierre B, de Labriolle A, Grimard C, Zannad N, Babuty D. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2008;51(8):828–35.

    CAS  PubMed  Google Scholar 

  111. Abuissa H, O’Keefe JH, Bybee KA. Statins as antiarrhythmics: a systematic review part I: effects on risk of atrial fibrillation. Clin Cardiol. 2009;32(10):544–8.

    PubMed  Google Scholar 

  112. Bhardwaj A, Sood NA, Kluger J, Coleman CI. Lack of effect of statins on maintenance of normal sinus rhythm following electrical cardioversion of persistent atrial fibrillation. Int J Clin Pract. 2010;64(8):1116–20.

    CAS  PubMed  Google Scholar 

  113. Dentali F, Gianni M, Squizzato A, Ageno W, Castiglioni L, Maroni L, et al. Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion. A systematic review and meta-analysis. Thromb Haemost. 2011;106(2):363–70.

    CAS  PubMed  Google Scholar 

  114. Loffredo L, Angelico F, Perri L, Violi F. Upstream therapy with statin and recurrence of atrial fibrillation after electrical cardioversion. Review of the literature and meta-analysis. BMC Cardiovasc Disord. 2012;12:107.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Disclosure

No external funding was used in the preparation of this manuscript and the authors report no conflicts of interest that might be relevant to the contents of this review.

Author information

Authors and Affiliations

  1. Department of Cardiology, St. George’s Hospital, Blackshaw Rd, SW17 0QT, London, UK

    Hanney Gonna & Mark M. Gallagher

Authors
  1. Hanney Gonna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark M. Gallagher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mark M. Gallagher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gonna, H., Gallagher, M.M. The Efficacy and Tolerability of Commonly Used Agents to Prevent Recurrence of Atrial Fibrillation After Successful Cardioversion. Am J Cardiovasc Drugs 14, 241–251 (2014). https://doi.org/10.1007/s40256-014-0064-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40256-014-0064-5

Keywords

Search

Navigation